Table II.
Clinical and molecular characteristics of all asymptomatic patients (n = 132)
| Characteristics | Upfront or concurrent RT (n = 46) | No RT before TKI treatment (n = 86) | P-value |
|---|---|---|---|
| Gender: | 0.484 | ||
| Male | 19 (41.3%) | 41 (47.7%) | |
| Female | 27 (58.7%) | 45 (52.3%) | |
| Age [years]: | 0.091 | ||
| < 65 | 36 (78.3%) | 31 (36.0%) | |
| ≥ 65 | 10 (21.7%) | 55 (64.0%) | |
| ECOG PS: | 0.747 | ||
| 0–1 | 41 (89.1%) | 75 (87.2%) | |
| 2 | 5 (10.9%) | 11 (12.8%) | |
| Smoking status: | 0.910 | ||
| Yes | 14 (30.4%) | 27 (31.4%) | |
| No | 32 (69.6%) | 59 (68.6%) | |
| Pathological type: | 0.297 | ||
| Adenocarcinomas | 46 (100.0%) | 84 (97.7%) | |
| Non-adenocarcinomas | 0 (0) | 2 (2.3%) | |
| Number of intracranial lesions: | 0.035 | ||
| 1–3 | 19 (41.3%) | 52 (73.2%) | |
| ≥ 3 | 27 (58.7%) | 34 (39.5%) | |
| RTOG GPA: | 0.960 | ||
| 0–1 | 12 (26.1%) | 23 (26.7%) | |
| 1.5–2.5 | 28 (60.9%) | 49 (57.0%) | |
| 3.0 | 4 (8.7%) | 9 (69.2%) | |
| 3.5–4.0 | 2 (4.3%) | 5 (5.8%) | |
| EGFR mutation: | 0.416 | ||
| Exon 19 | 28 (60.9%) | 46 (53.5%) | |
| Exon 21L858R | 18 (39.1%) | 40 (46.5%) | |
| Line of treatment of EGFR-TKI: | 0.170 | ||
| First line | 21 (45.7%) | 50 (58.1%) | |
| Second line or more | 25 (54.3%) | 36 (41.9%) | |
| Extracranial metastases: | 0.511 | ||
| Yes | 24 (52.2%) | 50 (58.1%) | |
| No | 22 (47.8%) | 36 (41.9%) | |